Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 65 out of 100. Mild cognitive impairment

Topic: Amyloid, tau and blood-test diagnosis

Plain-language summary

Regions with early signs of elevated amyloid β uptake were used to form an early, focal composite and compared to a commonly used global composite, in a separate validation sample. In a separate validation sample of 188 cognitively unimpaired individuals, the early, focal amyloid β PET composite showed a 120% increase in the accumulation rate of amyloid β compared to the global composite ( P < 0.001), resulting in a 60% increase in the power to detect a treatment effect in a primary prevention trial design. To detect early changes in amyloid β pathology, focusing on the earliest sites of amyloid β accumulation results in more powerful and efficient study designs in early Alzheimer's disease.

What this study adds

Evidence grade: Moderate

This is a follow-up (cohort) study of 279 participants. In a validation sample of 188 cognitively unimpaired individuals, focusing on the earliest sites of amyloid-β accumulation on PET increased the power to detect a treatment effect in a primary prevention trial design. It is about improving trial design for prevention research, not about a treatment or cure.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Insel, P. S., Mormino, E. C., Aisen, P. S., Thompson, W. K., & Donohue, M. C. (2020). Neuroanatomical spread of amyloid β and tau in Alzheimer's disease: implications for primary prevention. Brain communications. https://doi.org/10.1093/braincomms/fcaa007

Vancouver

Insel PS, Mormino EC, Aisen PS, Thompson WK, Donohue MC. Neuroanatomical spread of amyloid β and tau in Alzheimer's disease: implications for primary prevention. Brain communications. 2020. doi:10.1093/braincomms/fcaa007. PMID: 32140682.

BibTeX

@article{insel2020-32140682,
  author  = {Insel, P. S. and Mormino, E. C. and Aisen, P. S. and Thompson, W. K. and Donohue, M. C.},
  title   = {{Neuroanatomical spread of amyloid β and tau in Alzheimer's disease: implications for primary prevention}},
  journal = {Brain communications},
  year    = {2020},
  doi     = {10.1093/braincomms/fcaa007},
  pmid    = {32140682},
  url     = {https://doi.org/10.1093/braincomms/fcaa007}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.

Key findings

Why it matters

In a validation sample of 188 cognitively unimpaired individuals, focusing on the earliest sites of amyloid-β accumulation on PET increased the power to detect a treatment effect in a primary prevention trial design. It is about improving trial design for prevention research, not about a treatment or cure.

Study details

How this study scored 65/100
How this study's score is builtJournal tier 9 of 10; Journal's citation record 0 of 4; Study design 7 of 12; Strength of evidence 3 of 5; Peer-review validation 10 of 10; How recent 2 of 5; Sample size 2 of 4; Effect reported 0 of 3; Studied in people 3 of 3; Randomized / blinded 0 of 2; Times cited 5 of 7; Citations per year 3 of 5; Impact for its field and year 4 of 6; Cited by studies here 3 of 6; Still being cited 2 of 4; Senior author's track record 3 of 4; Institution's track record 3 of 3; Multicenter collaboration 2 of 3; Indexed in PubMed 2 of 2; Free to read 2 of 2. Total 65 of 100.65 of 100 points earned35 not earned

Published in a leading specialty journal, and it is a longitudinal study following the same people over time. Scored zero for effect reported and randomized / blinded because the record does not state it.

ComponentPointsWhy
Journal tier 9 / 10 Tier 2 — leading specialty journal (Brain communications)
Journal's citation record 0 / 4 Brain Communications: journal h-index 67 (OpenAlex, 2026-10-29)
Study design 7 / 12 A longitudinal study following the same people over time
Strength of evidence 3 / 5 Rated “moderate” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 2 / 5 2020 — within 10 year(s) of the newest study here
Sample size 2 / 4 279 participants
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 3 / 3 Studied in people (participant count stated)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 5 / 7 Cited 112 times (OpenAlex, 2026-10-10)
Citations per year 3 / 5 14.0 citations a year over 8 year(s) since 2020
Impact for its field and year 4 / 6 Cited 10.7× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 3 / 6 Cited by 10 other studies in this library
Still being cited 2 / 4 Cited 45 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 3 / 4 Last-listed author Michael Donohue: h-index 87 (OpenAlex, whole career)
Institution's track record 3 / 3 Stanford University: institution h-index 2,684 (OpenAlex)
Multicenter collaboration 2 / 3 OpenAlex lists 6 institution(s) in 2 countries
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 32140682)
Free to read 2 / 2 Free to read
Total 65 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 13.

Later studies that cite this one

10 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.

Related studies in Mild cognitive impairment from nearby years

Also tagged “precursor”

1,337 studies in the library carry the topic tag “precursor”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,337 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Mild cognitive impairment

See all studies in Mild cognitive impairment →